CA2465893A1 - Polycyclic guanine derivative phosphodiesterase v inhibitors - Google Patents

Polycyclic guanine derivative phosphodiesterase v inhibitors Download PDF

Info

Publication number
CA2465893A1
CA2465893A1 CA002465893A CA2465893A CA2465893A1 CA 2465893 A1 CA2465893 A1 CA 2465893A1 CA 002465893 A CA002465893 A CA 002465893A CA 2465893 A CA2465893 A CA 2465893A CA 2465893 A1 CA2465893 A1 CA 2465893A1
Authority
CA
Canada
Prior art keywords
group
alkyl
aryl
independently
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002465893A
Other languages
English (en)
French (fr)
Inventor
Theodros Asberom
John W. Clader
Yueqing Hu
Dmitri A. Pissarnitski
Andrew W. Stamford
Ruo Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2465893A1 publication Critical patent/CA2465893A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002465893A 2001-11-09 2002-11-07 Polycyclic guanine derivative phosphodiesterase v inhibitors Abandoned CA2465893A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34449801P 2001-11-09 2001-11-09
US60/344,498 2001-11-09
PCT/US2002/035721 WO2003042216A1 (en) 2001-11-09 2002-11-07 Polycyclic guanine derivative phosphodiesterase v inhibitors

Publications (1)

Publication Number Publication Date
CA2465893A1 true CA2465893A1 (en) 2003-05-22

Family

ID=23350773

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002465893A Abandoned CA2465893A1 (en) 2001-11-09 2002-11-07 Polycyclic guanine derivative phosphodiesterase v inhibitors

Country Status (7)

Country Link
US (2) US6943171B2 (enExample)
EP (1) EP1442042A1 (enExample)
JP (2) JP2005509038A (enExample)
CN (1) CN1585771A (enExample)
CA (1) CA2465893A1 (enExample)
MX (1) MXPA04004370A (enExample)
WO (1) WO2003042216A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1575916B1 (en) 2001-08-31 2013-05-22 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
US20050107394A1 (en) * 2001-12-17 2005-05-19 Ardeschir Ghofrani Novel use of selective pde5 inhibitors
SI1509525T1 (sl) * 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
CN101538224A (zh) * 2002-05-31 2009-09-23 先灵公司 制备黄嘌呤磷酸二酯酶v抑制剂及其前体的方法
MXPA06005681A (es) * 2003-11-21 2006-08-17 Schering Corp Formulaciones de inhibidores de la fosfodiesterasa v.
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
WO2006133261A2 (en) 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
US9012454B2 (en) 2005-12-09 2015-04-21 Mayo Foundation For Medical Education And Research Sexual dysfunction
WO2008063505A1 (en) 2006-11-13 2008-05-29 Intra-Cellular Therapies, Inc. Organic compounds
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
US20080261991A1 (en) 2007-02-12 2008-10-23 Dmi Biosciences, Inc. Reducing Side Effects of Tramadol
JP2010518167A (ja) 2007-02-12 2010-05-27 ディーエムアイ バイオサイエンシズ インコーポレイテッド 併存する早漏及び勃起障害の治療
US8349858B2 (en) * 2007-06-21 2013-01-08 Merck Sharp & Dohme Polycyclic guanine derivatives and use thereof
EP2939676A1 (en) 2007-12-06 2015-11-04 Intra-Cellular Therapies, Inc. Organic compounds
AU2009322903A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
PE20110922A1 (es) * 2008-12-06 2012-01-22 Intra Cellular Therapies Inc DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1)
EA201170769A1 (ru) 2008-12-06 2012-02-28 Интра-Селлулар Терапиз, Инк. Органические соединения
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
EP2434895A4 (en) * 2009-05-13 2013-08-07 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
WO2011016861A2 (en) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Novel regulatory proteins and inhibitors
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
EP2717877B1 (en) * 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
EP2956141A4 (en) 2013-02-17 2016-10-26 Intra Cellular Therapies Inc NEW USES
DK2970279T3 (da) 2013-03-15 2020-11-30 Intra Cellular Therapies Inc Organiske forbindelser
ES2717688T3 (es) 2013-03-15 2019-06-24 Intra Cellular Therapies Inc Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
DK3157926T3 (da) 2014-06-20 2019-08-19 Intra Cellular Therapies Inc Organiske forbindelser
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
CA2961212C (en) 2014-09-17 2024-02-06 Intra-Cellular Therapies, Inc. Compounds and methods
CN104262340B (zh) * 2014-09-19 2016-08-31 济南诚汇双达化工有限公司 一种他达拉非的制备方法
WO2016090382A1 (en) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Organic compounds
BR112017012007B1 (pt) 2014-12-06 2022-11-01 Intra-Cellular Therapies, Inc Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
CN105294733A (zh) * 2015-11-02 2016-02-03 上海伊贸斯生物材料有限公司 一种咪唑并噁嗪酮化合物及其制备方法和用途
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
US11291666B2 (en) 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
WO2020086481A1 (en) * 2018-10-21 2020-04-30 Intra-Cellular Therapies, Inc. Novel uses
US12410175B2 (en) 2019-09-03 2025-09-09 Intra-Cellular Therapies, Inc. Compounds
WO2021095945A1 (ko) * 2019-11-14 2021-05-20 순천향대학교 산학협력단 뇌졸중 또는 뇌졸중에 따른 후유증 치료를 위한 실데나필 및 rock 저해제의 용도
KR102336697B1 (ko) * 2019-11-14 2021-12-06 순천향대학교 산학협력단 실데나필 및 rock 저해제를 포함하는 뇌졸중으로 인한 운동 기능 손실의 치료용 약학적 조성물
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2116302A1 (en) 1970-12-07 1972-07-13 Brun Lab Sa Le 8-aminotheophyllines - with coronary - vasodilator bronchodilator diuretic, spasmolytic, antiinflammatory and analgesic activity
IT1217190B (it) 1988-04-22 1990-03-14 Recordati Chem Pharm Composti utili per il trattamento e diagnosi di disfunzioni frettili
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
FR2654935B1 (fr) 1989-11-28 1994-07-01 Lvmh Rech Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux.
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
NZ238609A (en) 1990-06-21 1993-12-23 Schering Corp Polycyclic guanine derivatives; preparation, pharmaceutical compositions,
GB9020959D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
GB9020921D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
ES2148170T3 (es) 1990-12-21 2000-10-16 Beecham Group Plc Derivados de xantina.
US5688768A (en) 1991-02-19 1997-11-18 Cor Therapeutics, Inc. Recombinant thrombin receptor and related pharmaceuticals
US5256766A (en) 1991-02-19 1993-10-26 The Regents Of The University Of California Recombinant thrombin receptor and related pharmaceuticals
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
EP0686157A1 (en) * 1993-02-26 1995-12-13 Schering Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9405518D0 (en) * 1994-03-21 1994-05-04 Mupor Ltd Porous metal composite body
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
EP0820441B1 (en) 1995-04-10 2002-06-26 Fujisawa Pharmaceutical Co., Ltd. INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US5824683A (en) 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
EP0882718B1 (en) 1995-12-28 2005-08-31 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
ATE215950T1 (de) 1996-05-10 2002-04-15 Icos Corp Carbolinderivate
WO1998008848A1 (en) 1996-08-30 1998-03-05 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinazoline derivatives
WO1998015530A1 (en) 1996-10-08 1998-04-16 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
US5874437A (en) 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
AU6230098A (en) 1997-02-27 1998-09-18 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
CA2288910C (en) 1997-04-25 2003-06-24 Pfizer Inc. Pyrazolopyrimidinones for sexual dysfunction
WO1999000359A1 (en) 1997-06-27 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. Aromatic ring derivatives
TW453999B (en) 1997-06-27 2001-09-11 Fujisawa Pharmaceutical Co Benzimidazole derivatives
WO1999021831A1 (en) 1997-10-27 1999-05-06 Fujisawa Pharmaceutical Co., Ltd. Tricyclic compounds as cgmp-pde inhibitors
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
AU734734B2 (en) 1997-10-28 2001-06-21 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
AU740758B2 (en) 1997-10-28 2001-11-15 Vivus, Inc. Treatment of female sexual dysfunction
US6037346A (en) 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
HU227841B1 (en) 1997-11-12 2012-05-02 Bayer Pharma AG 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof
RU2229476C2 (ru) 1998-02-19 2004-05-27 Эйсай Ко., Лтд. Производные фталазина и терапевтические средства для эректильной дисфункции
AU2641099A (en) 1998-02-27 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Imidazoquinazoline derivatives
AU2641199A (en) 1998-02-27 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Remedies for erectile dysfunction
ES2203078T3 (es) 1998-04-20 2004-04-01 Pfizer Inc. Parazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de la disfuncion sexual.
WO1999062905A1 (en) 1998-06-03 1999-12-09 Almirall Prodesfarma, S.A. 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
JP3827875B2 (ja) * 1999-01-27 2006-09-27 アルプス電気株式会社 メンブレンスイッチ
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
JP4450365B2 (ja) * 2001-08-28 2010-04-14 シェーリング コーポレイション 多環式グアニンホスホジエステラーゼｖ阻害剤

Also Published As

Publication number Publication date
WO2003042216A1 (en) 2003-05-22
CN1585771A (zh) 2005-02-23
JP2006077023A (ja) 2006-03-23
JP2005509038A (ja) 2005-04-07
US20030176413A1 (en) 2003-09-18
US6943171B2 (en) 2005-09-13
MXPA04004370A (es) 2004-08-11
EP1442042A1 (en) 2004-08-04
US20050171129A1 (en) 2005-08-04

Similar Documents

Publication Publication Date Title
US6943171B2 (en) Polycyclic guanine derivative phosphodiesterase V inhibitors
JP4450365B2 (ja) 多環式グアニンホスホジエステラーゼｖ阻害剤
CN104884458B (zh) 作为蛋白质激酶抑制剂的稠合杂环化合物
RU2302420C2 (ru) Ингибиторы ксантин-фосфодиэстеразы v, способ их получения, фармацевтическая композиция, применение и способ лечения
JP2013503191A (ja) ヤヌスキナーゼインヒビターとしての複素環式化合物
CN102388043A (zh) 组胺h3反相激动剂和拮抗剂及其使用方法
SK2592002A3 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
CN107106563B (zh) 化合物和方法
KR20040077885A (ko) 아자-아릴피페라진
CN111116492A (zh) 氘代苯甲氨嘧啶二酮衍生物及其用途
CN111727191A (zh) 取代的氮杂环丁烷二氢噻吩并吡啶类化合物及其作为磷酸二酯酶抑制剂的用途
CN111320633B (zh) 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途
JP2023532027A (ja) 新規な化合物およびこれを含む耐性がんの予防または治療用薬学組成物
CA3162355A1 (en) Substituted bicyclic and tricyclic ureas and amides, analogues thereof, and methods using same
TWI894448B (zh) Ctla-4小分子降解劑及其應用
TWI602818B (zh) 稠合雜環化合物作爲蛋白激酶抑制劑
TW202540108A (zh) Myt1激酶抑制劑化合物、其藥物組合物及其用途
CN106065018A (zh) 取代的吲哚化合物及其使用方法和用途
HK1064668B (en) Polycyclic guanine phosphodiesterase v inhibitors
EP1790652A1 (en) Polycyclic guanine phosphodiesterase V inhibitors
MX2011008349A (es) Agonistas y antagonistas inversos de histamina h3 y métodos para utilizarlos.

Legal Events

Date Code Title Description
FZDE Discontinued